Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Sep 10;28(1):33.
doi: 10.1038/s41533-018-0101-y.

Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients

Björn Ställberg  1 , Christer Janson  2 , Kjell Larsson  3 , Gunnar Johansson  4 , Konstantinos Kostikas  5 , Jean-Bernard Gruenberger  5 , Florian S Gutzwiller  5 , Leif Jorgensen  6 , Milica Uhde  7 , Karin Lisspers  4
Affiliations
Comparative Study

Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients

Björn Ställberg et al. NPJ Prim Care Respir Med. .

Abstract

This study aimed to generate real-world evidence to assess the burden of comorbidities in COPD patients, to effectively manage these patients and optimize the associated healthcare resource allocation. ARCTIC is a large, real-world, retrospective cohort study conducted in Swedish COPD patients using electronic medical record data collected between 2000 and 2014. These patients were studied for prevalence of various comorbidities and for association of these comorbidities with exacerbations, mortality, and healthcare costs compared with an age-, sex-, and comorbidities-matched non-COPD reference population. A total of 17,479 patients with COPD were compared with 84,514 non-COPD reference population. A significantly higher prevalence of various comorbidities was observed in COPD patients 2 years post-diagnosis vs. reference population, with the highest percentage increase observed for cardiovascular diseases (81.8% vs. 30.7%). Among the selected comorbidities, lung cancer was relatively more prevalent in COPD patients vs. reference population (relative risk, RR = 5.97, p < 0.0001). Ischemic heart disease, hypertension, depression, anxiety, sleep disorders, osteoporosis, osteoarthritis, and asthma caused increased mortality rates in COPD patients. Comorbidities that were observed to be significantly associated with increased number of severe exacerbations in COPD patients included heart failure, ischemic heart disease, depression/anxiety, sleep disorders, osteoporosis, lung cancer, and stroke. The cumulative healthcare costs associated with comorbidities over 2 years after the index date were observed to be significantly higher in COPD patients (€27,692) vs. reference population (€5141) (p < 0.0001). The data support the need for patient-centered treatment strategies and targeted healthcare resource allocation to reduce the humanistic and economic burden associated with COPD comorbidities.

PubMed Disclaimer

Conflict of interest statement

B.S. has received honoraria for educational activities and lectures from AstraZeneca, Boehringer Ingelheim, Meda, Novartis and Teva, and has served on advisory boards arranged by AstraZeneca, Novartis, Meda, GlaxoSmithKline, Teva and Boehringer Ingelheim. K.K., J.-B.G., and F.S.G. are employed by Novartis Pharma AG, Basel, Switzerland. C.J. has received honoraria for educational activities and lectures from Novartis, AstraZeneca, GlaxoSmithKline, TEVA and Boehringer Ingelheim outside the submitted work. G.J. has participated in the steering committee by Novartis for this study and served on advisory boards arranged by AstraZeneca, Novo Nordisk, and Takeda. K.L. has, during the last 5 years, on one or more occasion served in an advisory board and/or served as speaker and/or participated in education arranged by AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Orion, Novartis, TEVA and Takeda. L.J. and M.U. are employed by IQVIA. K.L. has received payments for educational activities and lectures from AstraZeneca, GlaxoSmithKline, Meda, MSD, Novartis and Nycomed, served on advisory boards arranged by Novartis and Meda, and has participated in the steering committee by Novartis for this study.

Figures

Fig. 1
Fig. 1
Prevalence of comorbidities (%) in COPD vs. reference population at 2 years pre- and post-first COPD diagnosis, #N = 52,208; *N = 13,052. COPD chronic obstructive pulmonary disease
Fig. 2
Fig. 2
HCRU in COPD patients vs. reference population-cumulative costs of 2 years after the index date, 2013, For the reference population, COPD-related costs include respiratory drugs mainly for asthma, COPD chronic obstructive pulmonary disease; EUR Euro; HCRU healthcare resource utilization
Fig. 3
Fig. 3
HCRU in COPD patients based on severity strata cohort COPD chronic obstructive pulmonary disease; GOLD Global Initiative for Chronic Obstructive Lung Disease; HCRU healthcare resource utilization
See this image and copyright information in PMC

References

    1. Adeloye D, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J. Glob. Health. 2015;5:020415. doi: 10.7189/jogh.05.020415. - DOI - PMC - PubMed
    1. Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128. doi: 10.1016/S0140-6736(12)61728-0. - DOI - PMC - PubMed
    1. GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, http://goldcopd.org/ (2017).
    1. Westerik JAM, et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir. Res. 2017;18:31. doi: 10.1186/s12931-017-0512-2. - DOI - PMC - PubMed
    1. Gudmundsson G, et al. Depression, anxiety and health status after hospitalisation for COPD: a multicentre study in the Nordic countries. Respir. Med. 2006;100:87–93. doi: 10.1016/j.rmed.2005.04.003. - DOI - PubMed

Publication types

LinkOut - more resources